论文部分内容阅读
目的:观察早期应用尼莫司汀对小细胞肺癌脑转移的预防作用。方法:小细胞肺癌患者60例随机分为A组和B组各30例。B组给予足叶乙甙联合卡铂化疗,每21 d为1个化疗周期,重复6个周期。A组在B组化疗方案基础上,于化疗第1,3,5个周期的第1天静脉滴注尼莫司汀2~3 mg/kg。比较2组脑转移发生率、客观缓解率、1 a生存率、无进展生存期和不良反应。结果:A组脑转移发生率低于B组(P<0.05)。2组客观缓解率和1 a生存率比较差异无统计学意义(P均>0.05)。A组无进展生存期高于B组(P<0.01),白细胞减少和恶心、呕吐发生率高于B组且程度较B组严重(P<0.05);2组血小板计数减少、贫血、周围神经炎和肾功能损害发生率比较差异无统计学意义(P>0.05)。结论:早期应用尼莫司汀可降低小细胞肺癌患者脑转移发生率。
Objective: To observe the preventive effect of nimustine on brain metastasis of small cell lung cancer in early stage. Methods: Sixty patients with small cell lung cancer were randomly divided into group A and group B, 30 cases each. Group B was given etoposide combined carboplatin chemotherapy, every 21 days for a chemotherapy cycle, repeat 6 cycles. Group A was treated with intravenous infusion of nimodipine 2 ~ 3 mg / kg on the first day of the first, third and fifth cycles of chemotherapy on the basis of group B chemotherapy. The incidence of brain metastases, objective response rate, 1-year survival rate, progression-free survival and adverse reactions were compared between the two groups. Results: The incidence of brain metastasis in group A was lower than that in group B (P <0.05). There was no significant difference in objective response rate and 1-year survival rate between the two groups (all P> 0.05). The progression-free survival rate of group A was higher than that of group B (P <0.01), and the incidence of leukopenia and nausea and vomiting was higher than that of group B (P <0.05). The reduction of platelet count, anemia, peripheral nerves The incidence of inflammation and renal dysfunction was no significant difference (P> 0.05). Conclusion: Early use of nimustine can reduce the incidence of brain metastases in patients with small cell lung cancer.